Silver Book Fact

Donepezil, a cholinesterase inhibitor, has been found to slow progression of Alzheimer’s disease in its early stages, delaying the need for nursing home care by an average of 30 months.

Provenzano G, Duttagupta S, McRae T, Mastey V, et al. Delays in Nursing Home Placement for Patients with Alzheimer s Disease Associated with Donepezil May Have Care Cost Savings Implications. Value in Health. 2001; 4(2): 158. https://www.valueinhealthjournal.com/article/S1098-3015(11)71392-4/abstract

Reference

Title
Delays in Nursing Home Placement for Patients with Alzheimer s Disease Associated with Donepezil May Have Care Cost Savings Implications
Publication
Value in Health
Publication Date
2001
Authors
Provenzano G, Duttagupta S, McRae T, Mastey V, et al
Volume & Issue
Volume 4, Issue 2
Pages
158
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Based on rates of admission in 1998, delaying admission of Alzheimer’s patients to nursing homes by 1 month could save as much as $1.12 billion a year.  
  • Medicare Costs, 5-Year Delayed Onset  
  • A study of rasagiline mesylate in Parkinson’s disease patients showed improved motor fluctuations and other Parkinson’s disease symptoms.  
  • A treatment breakthrough that slowed the progression of Alzheimer’s disease would reduce the number of people with the disease from 2.4 million to 1.1 million in 2020, and from 6.5…  
  • In one study, despite a 4-fold increase in prescription drug spending, overall health spending for Alzheimer’s patients undergoing drug therapy went down by 1/3.